Condition
TGCT
Total Trials
5
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (1)
P 2 (2)
P 3 (1)
Trial Status
Completed1
Active Not Recruiting1
Terminated1
Unknown1
Not Yet Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05417789Phase 3Active Not RecruitingPrimary
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
NCT06709911Not ApplicableNot Yet RecruitingPrimary
A Comparative Study of the Efficacy of Multimodal Interventions for Tenosynovitis
NCT05349643Phase 2Completed
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
NCT04938180Phase 2Terminated
A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
NCT05277454Phase 1Unknown
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
Showing all 5 trials